arrow
K

Karen A. Gelmon

bc cancer agency
H指数:106
被引数:5.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32

癌抗原15-3与加拿大癌症试验组MA.32中免疫组化定义的乳腺癌亚型远处复发的关系

2026-06-250
OAAI
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025

加拿大乳腺癌实践指南:2025年早期和转移性三阴性乳腺癌患者系统性治疗的国家共识建议

2026-04-270
OAAI
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Metastatic Breast Cancer 2025

加拿大乳腺癌实践指南:HR+/HER2−转移性乳腺癌患者系统性治疗的国家共识建议 2025

2026-02-150
OA
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
2025-11-010
OA
Corrigendum to “Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]

勘误:“Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]

2025-09-220
PREAI
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial

POSITIVE试验中,预测乳腺癌患者为尝试生育而中断辅助内分泌治疗时生育力的激素因素

2025-07-260
OAAI
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis

被诊断为非转移性乳腺癌的女性的转移性复发: 系统回顾和荟萃分析

2024-11-270
OAAI
Overall survival and updated invasive disease free survival results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2-breast cancer and residual disease after NACT

评估帕博西利比(palbociclib)对比安慰剂用于新辅助化疗后具有高危HR+/HER2-乳腺癌且存在残留病灶患者的研究Penelope-B试验的总体生存和更新的浸润性无病生存结果

2024-09-010
PRE